Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada
The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of
Read moreThe addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of
Read moreOTTAWA, ON / ACCESSWIRE / October 28, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug
Read moreSAINT LAURENT, Quebec, Oct. 21, 2020 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has
Read moreReduced the levels of key inflammatory cytokine markers Reduced fibrosis when the lung tissue was analyzed Reduced the effects of
Read moreTetra is ready to submit its first New Drug Submission application to commercialize a THC-based prescription drug in Canada. Will
Read moreOTTAWA, ON / ACCESSWIRE / September 11, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived
Read moreBrings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis space OTTAWA, ON /
Read morePharmaceutical GMP grade QIXLEEF™ shipped OTTAWA, ON / ACCESSWIRE / September 2, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF),
Read moreCanada NewsWire OTTAWA, ON, July 30, 2020 /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, July
Read moreNewsfile Corp.Newsfile Corp Phoenix, Arizona–(Newsfile Corp. – June 22, 2020) – The Stock Day Podcast welcomed Tetra Bio-Pharma (TSXV: TBP) (OTCQB:
Read moreOTTAWA, ON / ACCESSWIRE / June 3, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP)(OTCQB:TBPMF) and Altus Formulation Inc.
Read moreHCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma (HCC) OTTAWA, ON / ACCESSWIRE
Read more